Macquarie Group
RARX

Macquarie Group’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Macquarie Group’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,200
Closed -$10K – 2492
2017
Q4 		$10K Buy
+1,200
New +$14.8K ﹤0.01% 2269

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Macquarie Group's RARX Position: Q1 2018 in Review

Macquarie Group sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q1 2018, closing a stake of 1,200 shares — an estimated $10K sold.

Macquarie Group first reported a position in RARX in Q4 2017 and held it in 1 quarter. The position peaked at $10K in Q4 2017. 76 funds tracked by Wall St. Rank hold RARX as of Q1 2018.

  • Macquarie Group reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
  • Macquarie Group sold 1,200 Ra Pharmaceuticals, Inc. Common Stock shares in Q1 2018, an estimated $10K.
  • Macquarie Group first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 1 quarter.
  • Macquarie Group's Ra Pharmaceuticals, Inc. Common Stock position peaked at $10K in Q4 2017.
  • 76 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q1 2018.

Based on Macquarie Group's 13F filing for Q1 2018, filed 11 May 2018.